Contents In this issue 6 News & numbers


The vital headlines and statistics defining the industry.


Drug delivery 11 The best shot


The validation of Covid-19 vaccines will go down in history as a turning point during this pandemic, but with highly specific storage and transportation requirements, the roll-outs that followed have been anything but straightforward. The arrival of DNA vaccines could |help solve some of those issues, while delivering a host of other benefits. Tim Gunn speaks to Hong Jiang, COO of Aegis Life, and Luigi Aurisicchio, CEO of Takis Biotech, to find out how their technology could be an improvement on current vaccines.


14 Biosimilar interchangeability Owen Mumford


16 Innovative delivery of biologics Gerresheimer


19 Redefining the platform device model SHL Medical


20 Big issues, nano solutions Proteins and peptides have come a long way since their medicinal


29 Outsourcing


24 Tech transfer: from bottleneck to boon


Outsourcing arrangements have been crucial to the roll-out of Covid-19 vaccines, and the pandemic has focused the industry’s gaze on the importance of broader collaboration, truly effective outsourcing relationships and the need to


24 World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


potential was first realised, and yet oral delivery still faces age-old challenges. Andrew Tunnicliffe speaks with Professor David Brayden from University College Dublin, who uses nanotechnology to try to solve this problem, about some of the methods currently being researched with the aim of making oral delivery a reality.


avoid bottlenecks in the technical transfer phase. Sponsors and CDMOs need to be comfortable sharing the same brain, which means building trust, engaging in full disclosure and creating a platform for collaboration. Jim Banks speaks to Michael Mulkerrin, vice-president and head of CMC at ADC Therapeutics, to find out the ingredients of a smooth technical transfer.


27 Delivering efficient speed-to- market results Avéma Pharma Solutions


Chemicals & raw materials


28 The one-stop shop for peptides GL Biochem


29 Weighing the risks


Though vaccines are playing a huge role in the fight against Covid-19, some hesitancy remains. A few people have died from allergic reactions and blood clots likely sparked by the jab, but the plastering of such coverage on social media gives a narrow, rather than holistic, view of the risk. Andrea Valentino talks to Viktorija Erdeljic Turk at University Hospital Centre Zagreb and Lene Heise Garvey, an associate professor at the University of Copenhagen, to understand how the ingredients of vaccines might spark


5


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65